GS-6201 (CVT-6883) (4 mg/kg; i.p.; every 12 h for 14 days) significantly reduces IL-6, TNF-α, E-selectin, ICAM-1, and VCAM plasma levels[2].
GS-6201 (4 mg/kg; i.p.; every 12 h for 14 days) leads to a significant attenuation of left and right ventricular enlargement and dysfunction at 7 days, which was maintained at 14 days and also at 28 days[2].
GS-6201 (2 mg/kg; p.o.) treatment shows the Cmax, dAUC and t1/2 are 1110 ng/mL, 6500 ng h/mL, and 4.25 hours, respectively[1].
| Animal Model: | Adult out-bred male CD1 mice (8-12 weeks of age, AMI model)[2] |
| Dosage: | 4 mg/kg |
| Administration: | i.p.; every 12 h for 14 days |
| Result: | Significantly reduced IL-6, TNF-α, E-selectin, ICAM-1, and VCAM plasma levels. |
| Animal Model: | Sprague-Dawley rats[1] |
| Dosage: | 2 mg/kg |
| Administration: | p.o. (Pharmacokinetic Analysis) |
| Result: | The Cmax, dAUC and t1/2 were 1110 ng/mL, 6500 ng h/mL, and 4.25 hours, respectively. |
